Novartis are not going anywhere, I have it on good authority which I won't disclose so don't even ask me that they are here to stay and committed-the trials are one thing, but the benefits and science outweigh these false negatives due to badly designed trials- these trials will be restructured and designed properly in order to showcase the benefits. It's clear that regenerative has its place for Covid ards as well as standard ards.
Cell Therapy News/Articles, page-8793
-
- There are more pages in this discussion • 9,028 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.023(1.93%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $1.102M | 942.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 201639 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 39904 | 1 |
View Market Depth
| Last trade - 10.49am 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |